| 师 帅,李秀文,赵伊婷,赵 婷,马俨琦.左卡尼汀辅助持续低效缓慢血液透析治疗终末期糖尿病肾病的疗效及对患者生存质量和氧化应激指标的影响[J].,2024,(4):713-717 |
| 左卡尼汀辅助持续低效缓慢血液透析治疗终末期糖尿病肾病的疗效及对患者生存质量和氧化应激指标的影响 |
| Effect of L-carnitine Assisted Sustained Low-effciency Dialysis on End-stage DN and Its Influence on Quality of Life and Oxidative Stress Indicators of Patients |
| 投稿时间：2023-07-10 修订日期：2023-07-31 |
| DOI：10.13241/j.cnki.pmb.2024.04.022 |
| 中文关键词: 左卡尼汀 持续低效缓慢血液透析 糖尿病肾病 终末期 疗效 生存质量 氧化应激 |
| 英文关键词: L-carnitine Sustained low-effciency dialysis Diabetes nephropathy End-stage Efficacy Quality of life Oxidative stress |
| 基金项目:新疆维吾尔自治区自然科学基金项目（2019D01C274） |
|
| 摘要点击次数: 81 |
| 全文下载次数: 76 |
| 中文摘要: |
| 摘要 目的：评价左卡尼汀辅助持续低效缓慢血液透析（SLED）治疗终末期糖尿病肾病（DN）的疗效及对患者生存质量和氧化应激指标的影响。方法：选入我院2020年3月~2023年2月收治的终末期DN患者60例，随机分为对照组和观察组，各30例。两组均予以SLED治疗，观察组加用左卡尼汀，疗程3个月。评价两组的临床疗效、生存质量、氧化应激指标等，并进行统计比较。结果：观察组治疗总有效率较对照组高（P＜0.05），而不良反应总发生率较对照组低（P＜0.05）；观察组治疗后血清Na+、Alb显著高于对照组，K+、SCr、BUN、β2-MG水平明显低于对照组（P＜0.05）；相较于治疗前，两组治疗后MDA、AOPPs明显降低，SOD、GSP-Px显著升高（P＜0.05），而观察组降低/升高幅度明显大于对照组（P＜0.05）；两组治疗前SF-36量表评分无差异（P＞0.05），治疗后，观察组SF-36量表各项评分均显著高于对照组（P＜0.05）。结论：左卡尼汀辅助SLED治疗终末期DN的疗效明确，可有效抑制机体的氧化应激反应，减少不良反应，提高患者的生存质量。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate the efficacy of levocarnitine assisted sustained low-effciency dialysis (SLED) in the treatment of end-stage DN and its impact on patients' quality of life and oxidative stress indicators. Methods: Sixty end-stage DN patients admitted to our hospital from March 2020 to February 2023 were randomly divided into a matched group and an observation group, with 30 patients in each group. Both groups were treated with SLED, while the observation group was treated with levocarnitine for 3 months. Evaluate and compare the clinical efficacy, quality of life and oxidative stress indicators between the two groups. Results: The total effective rate of the observation group was higher than that of the matched group(P<0.05), while the total incidence of adverse reactions was lower than that of the matched group(P<0.05). After treatment, the serum Na+ and Alb levels in the observation group were higher than those in the matched group, while the K+, SCr, BUN and β2-MG levels were significantly lower than those in the matched group (P<0.05). Compared to before treatment, MDA and AOPPs were significantly reduced, while SOD and GSP-Px were significantly increased in both groups after treatment(P<0.05), while the decrease/increase amplitude in the observation group was greater than that in the matched group (P<0.05). There was no difference in the SF-36 scale scores between the two groups before treatment (P>0.05), but after treatment, the SF-36 scale scores in the observation group were higher than those in the matched group (P<0.05). Conclusion: The efficacy of levocarnitine assisted SLED in the treatment of end-stage DN is clear, which can effectively inhibit the body's oxidative stress response, reduce adverse reactions, and improve the quality of life of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
